{"uri": "eng-9427016", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Vaccine", "type": "wiki", "score": 100, "label": {"eng": "Vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/Clinical_trial", "type": "wiki", "score": 35, "label": {"eng": "Clinical trial"}}, {"uri": "http://en.wikipedia.org/wiki/Adjuvant", "type": "wiki", "score": 33, "label": {"eng": "Adjuvant"}}, {"uri": "http://en.wikipedia.org/wiki/COVID-19_vaccine", "type": "wiki", "score": 30, "label": {"eng": "COVID-19 vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/Rabies_vaccine", "type": "wiki", "score": 28, "label": {"eng": "Rabies vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/Virus", "type": "wiki", "score": 28, "label": {"eng": "Virus"}}, {"uri": "http://en.wikipedia.org/wiki/China", "type": "loc", "score": 28, "label": {"eng": "China"}, "location": {"type": "country", "label": {"eng": "China"}}}, {"uri": "http://en.wikipedia.org/wiki/Public_health", "type": "wiki", "score": 25, "label": {"eng": "Public health"}}, {"uri": "http://en.wikipedia.org/wiki/Hong_Kong", "type": "loc", "score": 25, "label": {"eng": "Hong Kong"}, "location": {"type": "country", "label": {"eng": "Hong Kong"}}}, {"uri": "http://en.wikipedia.org/wiki/Infection", "type": "wiki", "score": 24, "label": {"eng": "Infection"}}, {"uri": "http://en.wikipedia.org/wiki/Conjugate_vaccine", "type": "wiki", "score": 23, "label": {"eng": "Conjugate vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/Valneva_COVID-19_vaccine", "type": "wiki", "score": 21, "label": {"eng": "Valneva COVID-19 vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/Ploidy", "type": "wiki", "score": 21, "label": {"eng": "Ploidy"}}, {"uri": "http://en.wikipedia.org/wiki/Phases_of_clinical_research", "type": "wiki", "score": 21, "label": {"eng": "Phases of clinical research"}}, {"uri": "http://en.wikipedia.org/wiki/Immunogenicity", "type": "wiki", "score": 20, "label": {"eng": "Immunogenicity"}}, {"uri": "http://en.wikipedia.org/wiki/Zika_virus", "type": "wiki", "score": 20, "label": {"eng": "Zika virus"}}, {"uri": "http://en.wikipedia.org/wiki/Inactivated_vaccine", "type": "wiki", "score": 18, "label": {"eng": "Inactivated vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/Recombinant_DNA", "type": "wiki", "score": 18, "label": {"eng": "Recombinant DNA"}}, {"uri": "http://en.wikipedia.org/wiki/Research_and_development", "type": "wiki", "score": 18, "label": {"eng": "Research and development"}}, {"uri": "http://en.wikipedia.org/wiki/MRNA_vaccine", "type": "wiki", "score": 17, "label": {"eng": "MRNA vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/Immunization", "type": "wiki", "score": 17, "label": {"eng": "Immunization"}}, {"uri": "http://en.wikipedia.org/wiki/Hepatitis_B_vaccine", "type": "wiki", "score": 16, "label": {"eng": "Hepatitis B vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/United_States", "type": "loc", "score": 15, "label": {"eng": "United States"}, "location": {"type": "country", "label": {"eng": "United States"}}}, {"uri": "http://en.wikipedia.org/wiki/Europe", "type": "loc", "score": 14, "label": {"eng": "Europe"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/Norway", "type": "loc", "score": 10, "label": {"eng": "Norway"}, "location": {"type": "country", "label": {"eng": "Norway"}}}, {"uri": "http://en.wikipedia.org/wiki/Louisiana", "type": "loc", "score": 9, "label": {"eng": "Louisiana"}, "location": {"type": "place", "label": {"eng": "Louisiana"}, "country": {"type": "country", "label": {"eng": "United States"}}}}, {"uri": "http://en.wikipedia.org/wiki/Southeast_Asia", "type": "loc", "score": 8, "label": {"eng": "Southeast Asia"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/South_America", "type": "loc", "score": 8, "label": {"eng": "South America"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/Africa", "type": "loc", "score": 8, "label": {"eng": "Africa"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/Merck_&_Co.", "type": "org", "score": 6, "label": {"eng": "Merck & Co."}}], "eventDate": "2024-03-26", "totalArticleCount": 25, "title": {"eng": "AIM Vaccine Announces 2023 Annual Results"}, "summary": {"eng": "Three Highly Anticipated Flagship Upgraded Vaccines Filing for Market Listing; Significant Breakthrough Achieved in the International Market\n\nHONG KONG SAR -\n\nMedia OutReach Newswire - 28 March 2024 - AIM Vaccine Co., Ltd. (the \"Company\", together with its subsidiaries, the \"Group\") is pleased to announce the results for the year ended 31 December 2023 (the \"Period\").\n\nAs of December 31, 2023, AIM Vaccine has obtained a total of 14 clinical approvals and conducted 21 clinical trials. Among them, "}, "location": null, "categories": [{"uri": "dmoz/Health/Conditions_and_Diseases/Infectious_Diseases", "label": "dmoz/Health/Conditions and Diseases/Infectious Diseases", "wgt": 93}, {"uri": "dmoz/Health/Child_Health/Immunizations", "label": "dmoz/Health/Child Health/Immunizations", "wgt": 92}, {"uri": "dmoz/Health/Animal/Livestock", "label": "dmoz/Health/Animal/Livestock", "wgt": 91}, {"uri": "news/Health", "label": "news/Health", "wgt": 65}], "articleCounts": {"eng": 25}, "sentiment": 0.223529411764706, "wgt": 449107200, "relevance": 2}